Loading…
Trial eligibility change
| eligibility_criteria | Inclusion Criteria: Healthy Participants Healthy participants between the ages of 18 and 55 years. * Have body weight of at least 50 kilograms (kg) and body mass index (BMI) between 18 and 32 kilogram per square meter (kg/m²), inclusive. Participants with Systemic Lupus Erythematosus (SLE) * Are 18 to 75 years of age, inclusive. * Have body weight between 45 and 145 kg, inclusive, and BMI between 18 and 35 kg/m², inclusive. * Have a clinical diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria at least 6 months prior to screening. Participants with Rheumatoid Arthritis (RA) * Are 18 to 75 years of age, inclusive. * Have body weight between 45 and 145 kg, inclusive, and BMI between 18 and 35 kg/m², inclusive. * Have a diagnosis of adult-onset RA for at least 6 months prior to screening, as defined by the 2010 ACR/EULAR classification criteria * Have Disease Activity Score in 28 joints (DAS28)-high-sensitivity C-reactive protein (hsCRP) greater than or equal to 4.4. * Have positive test results for rheumatoid factor or anti-citrullinated peptide antibodies * Have had a history of failure (an inadequate response, intolerance, or loss of response) to at least 2 advanced therapies (biological disease-modifying antirheumatic drug \[bDMARD\] or targeted synthetic DMARD \[tsDMARD\]) after failing a conventional synthetic DMARD (csDMARD). Exclusion Criteria: * Have known allergies to LY4298445, related compounds, or any components of the formulation * Are individuals assigned female at birth (AFAB) who are lactating or have a positive pregnancy test at screening or Day -1. * Have severe active lupus-associated renal disease (lupus nephritis) defined clinically and/or by * urine protein/creatinine ratio greater than 200 milligrams per millimole (mg/mmol) (as an estimate of approximate proteinuria greater than 2 reams (g) per day) or * an estimated glomerular filtration rate (eGFR) less than 40 milliliters per minute (mL/min)/1.73 m² at screening, as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) 2021. * requiring hemodialysis within 6 months prior to screening * Have active central nervous system lupus as defined by ACR nomenclature for neuropsychiatric lupus syndromes and as captured by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, and cerebrovascular accident, within 2 months prior to screening * Have a Class 4 RA according to the ACR revised criteria | → | Inclusion Criteria: Healthy Participants Healthy participants between the ages of 18 and 55 years. * Have body weight of at least 50 kilograms (kg) and body mass index (BMI) between 18 and 32 kilogram per square meter (kg/m²), inclusive. Participants with Systemic Lupus Erythematosus (SLE) * Are 18 to 75 years of age, inclusive. * Have body weight between 45 and 145 kg, inclusive, and BMI between 18 and 35 kg/m², inclusive. * Have a clinical diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria at least 6 months prior to screening. Participants with Rheumatoid Arthritis (RA) * Are 18 to 75 years of age, inclusive. * Have body weight between 45 and 145 kg, inclusive, and BMI between 18 and 35 kg/m², inclusive. * Have a diagnosis of adult-onset RA for at least 6 months prior to screening, as defined by the 2010 ACR/EULAR classification criteria * Have Disease Activity Score in 28 joints (DAS28)-high-sensitivity C-reactive protein (hsCRP) greater than or equal to 3.2. * Have positive test results for rheumatoid factor or anti-citrullinated peptide antibodies * Have had a history of failure (an inadequate response, intolerance, or loss of response) to at least 2 advanced therapies (biological disease-modifying antirheumatic drug \[bDMARD\] or targeted synthetic DMARD \[tsDMARD\]) after failing a conventional synthetic DMARD (csDMARD). Exclusion Criteria: * Have known allergies to LY4298445, related compounds, or any components of the formulation * Are individuals assigned female at birth (AFAB) who are lactating or have a positive pregnancy test at screening or Day -1. * Have severe active lupus-associated renal disease (lupus nephritis) defined clinically and/or by * urine protein/creatinine ratio greater than 200 milligrams per millimole (mg/mmol) (as an estimate of approximate proteinuria greater than 2 reams (g) per day) or * an estimated glomerular filtration rate (eGFR) less than 40 milliliters per minute (mL/min)/1.73 m² at screening, as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) 2021. * requiring hemodialysis within 6 months prior to screening * Have active central nervous system lupus as defined by ACR nomenclature for neuropsychiatric lupus syndromes and as captured by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus headache, and cerebrovascular accident, within 2 months prior to screening * Have a Class 4 RA according to the ACR revised criteria |
Not scored.No materiality record exists yet for this event.
No other named entities identified.This event has no scored competitor read-through.
No real valuation-relevant phase transition on a resolved asset for this event.This section fires only when the event carries a resolved asset and a real phase change — not guessed for every event.